Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.

Al-Kawaaz M, Sanchez T, Kluk MJ.

J Hematop. 2019 Jun;12(2):57-65. doi: 10.1007/s12308-019-00354-y. Epub 2019 Apr 27.

PMID:
31404445
2.

Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!

Kluk MJ, Bagg A.

J Mol Diagn. 2019 Jan;21(1):13-15. doi: 10.1016/j.jmoldx.2018.09.001. Epub 2018 Oct 19.

PMID:
30347269
3.

A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.

Ryan RJH, Petrovic J, Rausch DM, Zhou Y, Lareau CA, Kluk MJ, Christie AL, Lee WY, Tarjan DR, Guo B, Donohue LKH, Gillespie SM, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM, Faryabi RB, Bernstein BE, Aster JC, Pear WS.

Cell Rep. 2017 Oct 17;21(3):784-797. doi: 10.1016/j.celrep.2017.09.066.

4.

Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid Neoplasms.

Ho C, Kluk MJ.

Surg Pathol Clin. 2016 Sep;9(3):489-521. doi: 10.1016/j.path.2016.04.011. Review.

PMID:
27523974
5.

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.

Kluk MJ, Lindsley RC, Aster JC, Lindeman NI, Szeto D, Hall D, Kuo FC.

J Mol Diagn. 2016 Jul;18(4):507-15. doi: 10.1016/j.jmoldx.2016.02.003.

6.

Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.

Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, Capodieci P, Deplazes-Lauber J, Petropoulos K, Thiel P, Ponsel D, Hee Choi S, LeMotte P, London A, Goetcshkes M, Nolin E, Jones MD, Slocum K, Kluk MJ, Weinstock DM, Christodoulou A, Weinberg O, Jaehrling J, Ettenberg SA, Buckler A, Blacklow SC, Aster JC, Fryer CJ.

Oncogene. 2016 Nov 24;35(47):6077-6086. doi: 10.1038/onc.2016.133. Epub 2016 May 9.

7.

Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay.

Kluk MJ, Abo RP, Brown RD, Kuo FC, Dal Cin P, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, Aster JC.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000307. doi: 10.1101/mcs.a000307.

8.

MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.

Kluk MJ, Ho C, Yu H, Chen BJ, Neuberg DS, Dal Cin P, Woda BA, Pinkus GS, Rodig SJ.

Am J Clin Pathol. 2016 Feb;145(2):166-79. doi: 10.1093/ajcp/aqv028. Epub 2016 Feb 1.

PMID:
26834124
9.

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.

Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE.

Nat Genet. 2016 Mar;48(3):265-72. doi: 10.1038/ng.3502. Epub 2016 Feb 1.

10.

Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke.

Kim GS, Yang L, Zhang G, Zhao H, Selim M, McCullough LD, Kluk MJ, Sanchez T.

Nat Commun. 2015 Aug 5;6:7893. doi: 10.1038/ncomms8893.

11.

Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, Neuberg D, Sohani AR, Shipp MA, Monti S, Rodig SJ.

J Mol Diagn. 2015 Jan;17(1):19-30. doi: 10.1016/j.jmoldx.2014.08.006. Epub 2014 Nov 7.

12.

Age-related clonal hematopoiesis associated with adverse outcomes.

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL.

N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.

13.

Cyclin C is a haploinsufficient tumour suppressor.

Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, Gutierrez A, Ordureau A, Otto T, Kreslavsky T, Baitsch L, Bury L, Meyer CA, Ke N, Mulry KA, Kluk MJ, Roy M, Kim S, Zhang X, Geng Y, Zagozdzon A, Jenkinson S, Gale RE, Linch DC, Zhao JJ, Mullighan CG, Harper JW, Aster JC, Aifantis I, von Boehmer H, Gygi SP, Wei W, Look AT, Sicinski P.

Nat Cell Biol. 2014 Nov;16(11):1080-91. doi: 10.1038/ncb3046. Epub 2014 Oct 26.

14.

NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis.

South AP, Purdie KJ, Watt SA, Haldenby S, den Breems N, Dimon M, Arron ST, Kluk MJ, Aster JC, McHugh A, Xue DJ, Dayal JH, Robinson KS, Rizvi SH, Proby CM, Harwood CA, Leigh IM.

J Invest Dermatol. 2014 Oct;134(10):2630-2638. doi: 10.1038/jid.2014.154. Epub 2014 Mar 24.

15.

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.

Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein BE.

Nat Genet. 2014 Apr;46(4):364-70. doi: 10.1038/ng.2913. Epub 2014 Mar 2.

16.

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.

Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC.

PLoS One. 2013 Jun 18;8(6):e67306. doi: 10.1371/journal.pone.0067306. Print 2013.

17.

Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation.

Zhang G, Yang L, Kim GS, Ryan K, Lu S, O'Donnell RK, Spokes K, Shapiro N, Aird WC, Kluk MJ, Yano K, Sanchez T.

Blood. 2013 Jul 18;122(3):443-55. doi: 10.1182/blood-2012-11-467191. Epub 2013 May 30.

18.

MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.

Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM, Aserlind AB, Wang H, Evan G, Kluk MJ, Bradner JE, Aster JC, French CA.

Oncogene. 2014 Mar 27;33(13):1736-1742. doi: 10.1038/onc.2013.126. Epub 2013 Apr 22.

19.

Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration.

Kluk MJ, Ryan KP, Wang B, Zhang G, Rodig SJ, Sanchez T.

Lab Invest. 2013 Apr;93(4):462-71. doi: 10.1038/labinvest.2013.7. Epub 2013 Feb 18.

20.

Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.

Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP.

J Clin Oncol. 2012 Jul 1;30(19):2340-7. doi: 10.1200/JCO.2011.38.7340. Epub 2012 May 14.

21.

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas.

Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ.

PLoS One. 2012;7(4):e33813. doi: 10.1371/journal.pone.0033813. Epub 2012 Apr 12.

22.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

23.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS.

JAMA. 2011 Nov 23;306(20):2221-8. doi: 10.1001/jama.2011.1703. Epub 2011 Nov 16.

PMID:
22088980
24.

TCR-dependent transformation of mature memory phenotype T cells in mice.

Wang X, Werneck MB, Wilson BG, Kim HJ, Kluk MJ, Thom CS, Wischhusen JW, Evans JA, Jesneck JL, Nguyen P, Sansam CG, Cantor H, Roberts CW.

J Clin Invest. 2011 Oct;121(10):3834-45. doi: 10.1172/JCI37210. Epub 2011 Sep 19.

25.

Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations.

Poitras JL, Costa D, Kluk MJ, Amrein PC, Stone RM, Lee C, Dal Cin P, Morton CC.

Cancer Genet. 2011 Feb;204(2):68-76. doi: 10.1016/j.cancergen.2010.12.005.

PMID:
21504705
26.

Avoiding pitfalls in molecular genetic testing: case studies of high-resolution array comparative genomic hybridization testing in the definitive diagnosis of Mowat-Wilson syndrome.

Kluk MJ, An Y, James P, Coulter D, Harris D, Wu BL, Shen Y.

J Mol Diagn. 2011 May;13(3):363-7. doi: 10.1016/j.jmoldx.2011.01.008.

27.

Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors.

Cannizzo E, Sohani AR, Ferry JA, Hochberg EP, Kluk MJ, Dorn ME, Sadowski C, Bucci JJ, Ackerman AM, Longtine JA, Carulli G, Preffer FI.

J Hematop. 2009 Jul 23;2(3):163-70. doi: 10.1007/s12308-009-0041-0.

28.

Melanoma on the move: the progression of melanoma: novel concepts with histologic correlates.

Kluk MJ, Grant-Kels JM, Kerr P, Hoss D, Berke A, Claffey KP, Murphy M.

Am J Dermatopathol. 2004 Dec;26(6):504-10. Review. No abstract available.

PMID:
15618934
30.

Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors.

Kluk MJ, Hla T.

Biochim Biophys Acta. 2002 May 23;1582(1-3):72-80. Review.

PMID:
12069812
31.

Lysophospholipids--receptor revelations.

Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ.

Science. 2001 Nov 30;294(5548):1875-8. Review.

PMID:
11729304
32.

Supplemental Content

Support Center